相似文献
1
Incidental Detection of Medullary Thyroid Carcinoma by 68Ga-DOTATATE PET/CT in a Patient With Neuroendocrine Tumor Liver Metastases.
Clin Nucl Med. 2018 Feb;43(2):136-138. doi: 10.1097/RLU.0000000000001950.
2
Calcitonin-Negative Neuroendocrine Tumor of the Thyroid on 68Ga DOTANOC PET-CT.
Clin Nucl Med. 2019 Sep;44(9):e546-e547. doi: 10.1097/RLU.0000000000002698.
3
Clinical impact of Ga-DOTATATE PET-CT imaging in patients with medullary thyroid cancer.
Ann Nucl Med. 2020 Sep;34(9):663-674. doi: 10.1007/s12149-020-01494-3. Epub 2020 Jun 29.
4
Incidental Uptake in Benign Gynecomastia on 68Ga-DOTATATE PET/CT.
Clin Nucl Med. 2019 Oct;44(10):799-800. doi: 10.1097/RLU.0000000000002597.
5
Hepatocellular Carcinoma Mimicking Neuroendocrine Tumor Metastasis on 68Ga-DOTATATE PET/CT.
Clin Nucl Med. 2019 Apr;44(4):330-331. doi: 10.1097/RLU.0000000000002467.
6
Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Clin Nucl Med. 2014 Jun;39(6):505-10. doi: 10.1097/RLU.0000000000000429.
7
The role of tumour biomarkers in choosing the appropriate positron emission tomography imaging in follow-up of medullary thyroid cancer.
J Med Imaging Radiat Oncol. 2020 Dec;64(6):756-761. doi: 10.1111/1754-9485.13081. Epub 2020 Jul 12.
8
MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with Ga-DOTATATE and F-FDG and Multimodality Anatomic Imaging in Metastatic Neuroendocrine Tumors of Unknown Primary in a PRRT Workup Setting.
J Nucl Med Technol. 2017 Mar;45(1):34-41. doi: 10.2967/jnmt.116.185777. Epub 2017 Feb 2.
9
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice.
J Vis Exp. 2019 Apr 17(146). doi: 10.3791/59358.
10
Long-Acting Somatostatin Analog Therapy Differentially Alters Ga-DOTATATE Uptake in Normal Tissues Compared with Primary Tumors and Metastatic Lesions.
J Nucl Med. 2018 Feb;59(2):223-227. doi: 10.2967/jnumed.117.192203. Epub 2017 Jul 20.
引用本文的文献
1
Prevalence and significance of incidental findings on 68 Ga-DOTA-conjugated somatostatin receptor-targeting peptide PET/CT: a systematic review of the literature.
Cancer Imaging. 2022 Sep 3;22(1):44. doi: 10.1186/s40644-022-00484-0.
本文引用的文献
1
Guideline for PET/CT imaging of neuroendocrine neoplasms with Ga-DOTA-conjugated somatostatin receptor targeting peptides and F-DOPA.
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1588-1601. doi: 10.1007/s00259-017-3728-y. Epub 2017 May 25.
2
Most of the Intended Management Changes After Ga-DOTATATE PET/CT Are Implemented.
J Nucl Med. 2017 Nov;58(11):1793-1796. doi: 10.2967/jnumed.117.192450. Epub 2017 May 4.
3
The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom.
J Nucl Med. 2016 Jan;57(1):34-40. doi: 10.2967/jnumed.115.166017. Epub 2015 Oct 15.
4
Incidence of Second Primary Malignancies in Patients with Neuroendocrine Tumours.
Neuroendocrinology. 2015;102(1-2):26-32. doi: 10.1159/000381716. Epub 2015 Mar 21.
5
Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician's perspective.
J Nucl Med. 2015 Jan;56(1):70-5. doi: 10.2967/jnumed.114.148247. Epub 2014 Dec 11.
6
Second cancers in patients with neuroendocrine tumors.
PLoS One. 2013 Dec 31;8(12):e86414. doi: 10.1371/journal.pone.0086414. eCollection 2013.
7
The risk of metachronous cancers in patients with small-intestinal carcinoid tumors: a US population-based study.
Endocr Relat Cancer. 2012 May 24;19(3):381-7. doi: 10.1530/ERC-11-0392. Print 2012 Jun.
8
Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract and pancreas.
Endocr Relat Cancer. 2012 Feb 13;19(1):95-9. doi: 10.1530/ERC-11-0315. Print 2012 Feb.
9
Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives.
J Clin Endocrinol Metab. 2006 Jun;91(6):2218-24. doi: 10.1210/jc.2006-0334. Epub 2006 Mar 28.
10
Neuroendocrine tumors and second primary malignancy--a relationship with clinical impact?
Anticancer Res. 2004 Mar-Apr;24(2C):1049-51.
Zotero 插件